ClinicalTrials.gg
RecruitingNCT07203391TRIUMPHUpdated Nov 18, 2026

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

A Phase 1 interventional study of roginolisib in Uveal Melanoma, Metastatic, sponsored by St Vincent's Hospital, Sydney. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by St Vincent's Hospital, Sydney · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Uveal Melanoma with a site in Australia — 8 open to participants now, 15 under way, 5 of them phase 3. Uveal Melanoma · Australia.

Planned enrollment
18th of 20
8 · median 108
Started
2026
with 2 others
Phase 1
7 of 22
2 open now
Primary completion
2027-12
later than 9 of 14 live
Registered
20th of 22
by date
Lead sponsor
3 of 22
St Vincent's Hospital, Sydney

Among the 22 studies in Uveal Melanoma with a site in Australia, this one is the 18th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 9 of the 14 other live ones, and was the 20th registered.

Uveal Melanoma

281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.

Browse Uveal Melanoma studies →

Open to participants now

8 of the 22 studies in Uveal Melanoma with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Uveal Melanoma with a site in Australia, or all of them as a file.
02

Study summary

This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib

Read the detailed description

Based on the established activity of Tebentafusp, and the promising action of Roginolisib, this trial combines the two drugs from cycle 4 onwards in patients with metastatic uveal melanoma

03

Conditions studied

  • Uveal Melanoma, Metastatic

Keywords

  • tebentafusp
  • Roginolisib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants must be aged 18 years or over at the time, to be eligible to participate in this study.
  2. or cytologically confirmed UM or unresectable UM patients
  3. HLA-A*02:01 positive
  4. (ECOG) Performance Status of 0 or 1
  5. Currently undergoing treatment for mUM with tebentafusp
  6. Tebentafusp related toxicity, including cytokine release syndrome that has resolved to grade ≤ 1 as per v5.0.
  7. Male and female participants of who are sexually active with a non-sterilized partner must agree to use highly effective methods of (eg double barrier) from the trial screening date until 6 months after the final dose of the program intervention; cessation of birth control after this point shall be discussed with a responsible physician.
  8. Pregnant or lactating women are prohibited from enrolling on this program.
  9. Male participants are not allowed to donate sperm from the time of enrolment until 6 months post- administration of program interventions.

Exclusion criteria

Exclusion Criteria:

  1. Presence of untreated or symptomatic central nervous system (CNS) , , or cord compression. NOTE: Participants with treated CNS lesions may enroll provided all of the following apply:

    1. Treated CNS lesions must be radiographically stable for ≥ 4 weeks after intervention (surgery and/or radiation).
    2. Participants must be neurologically stable off systemic for at least 2 weeks prior to trial entry
  2. Ongoing Grade 2 or greater treatment related toxicity due to tebentafusp
  3. Prior treatment with a PI3Kδ inhibitor
  4. Prior Grade 4 cytokine release syndrome related to Tebentafusp
  5. Systemic treatment with steroids or any other drug use within 2 weeks of the planned first dose of program intervention, with the following exceptions:

    1. Treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ≤ 10 mg daily or the equivalent.
    2. Local or topical steroid therapies (eg, optic, ophthalmic, intra- articular, or inhaled medications) are acceptable.
    3. Premedication for allergy to contrast reagent.
  6. Any relevant medical condition, which in the opinion of the treating physician, would prevent the participant enrolling into the Program due to concerns related to safety, compliance with procedures, or interpretation of program results.
  7. Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
  8. Chronic viral infections as indicated below. NOTE: Testing for (HIV), virus (HBV), and virus (HCV) status prior to enrollment is not necessary unless clinically indicated.
  9. Known HIV infection unless all of the following are applicable:

    1. Receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥3 months prior to the planned first study intervention
    2. >350 cells/µl
    3. CD4 T-cell nadir (lowest historical count) \< 350 cells/µl
    4. Viral load confirmed as \<50 copies/ml during Screening.
  10. Known HBV infection, unless on stable anti-viral therapy for > 4 weeks prior to the planned first dose of program intervention and viral load confirmed as undetectable during Screening.
  11. Known HCV infection, unless the participant has received curative treatment, and viral load was confirmed as undetectable during Screening.
  12. Participant with an out-of-range Screening laboratory values defined as shown below. NOTE: Hematology evaluations must be performed ≥ 7 days from any blood or blood product transfusion and ≥ 14 days from any dose of hematologic growth factor.

    1. (calculated using Cockcroft-Gault formula, or measured) \< 30 mL/minute.
    2. Total > 1.5 × , except for patients with Gilbert's syndrome who are excluded if total bilirubin > 3.0 × ULN or direct bilirubin > 1.5 × ULN.
    3. > 5 × ULN in the presence of liver metastases; > 3 X ULN if not
    4. Aspartate aminotransferase > 5 × ULN in the presence of liver metastases ; > 3 X ULN if not
    5. count \< 75 × 109/L
    6. \< 9 g/dL
  13. cardiac disease or impaired cardiac function, including any of the following:

    1. Congestive heart failure ( Class ≥ 3)
    2. >470msec at baseline
    3. Uncontrolled hypertension defined as systolic blood pressure [BP] > 160 mmHg or diastolic BP > 110 mmHg with the following requirements:
    4. If initial measurement is elevated, additional assessments should be taken where each assessment is the mean value of 3 measurements taken at least 5 minutes apart.
    5. Eligibility is based on the average of at least 2 assessments taken at least 1 hour apart.
    6. Acute myocardial infarction or unstable angina pectoris \< 6 months prior to the planned first dose of program intervention.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Combination

    Tebentafusp/ Roginolisib

    Drug: roginolisib

Interventions

  • Investigational combination - initially at 40mg (Dose 1) then 80mg (Dose 2)

06

What researchers measure

Primary outcomes

  1. • To determine the safety and tolerability of roginolisib and tebentafusp in HLA-A*02:01 positive patients advanced uveal melanoma (UM).

    CTCAE V5.0

    Time frame: Through study completion, estimated average of 1 year

  2. • To establish a maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of roginolisib and tebentafusp in HLA-A*02:01 positive patients advanced uveal melanoma (UM).

    As determined by DSMB

    Time frame: Through study completion, estimated average of 1 year

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Confidentiality

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 32 phase 1 interventional studies under Uveal Melanoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 66. This study's planned 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2025
First posted
Oct 2, 2025
StartActual
Feb 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07203391
Lead sponsor
St Vincent's Hospital, Sydney
Responsible party
Anthony Joshua, FRACP (Professor, St Vincent's Hospital, Sydney) — Principal investigator
First posted
Oct 2, 2025
Start date
Feb 1, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Anthony Joshua, MBBS PhD FRACP
principal investigator · St Vinents Hospital sydney

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roginolisib

Start the discussion